WEBULL
News
MIST
2.050
+1.49%
0.030
Weekly Report: what happened at MIST last week (1222-1226)?
Weekly Report · 12/29/2025 09:13
Weekly Report: what happened at MIST last week (1215-1219)?
Weekly Report · 12/22/2025 09:13
AptarGroup Announces That Its Bidose Liquid Nasal Spray System Liquid Is The Mechanism For Delivering The Newly Approved CARDAMYST
Benzinga · 12/17/2025 22:15
AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment
Reuters · 12/17/2025 22:00
Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed?
Simply Wall St · 12/17/2025 15:19
Milestone Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Dow Jones · 12/16/2025 15:12
Milestone Pharmaceuticals Price Target Raised to $8.00/Share From $4.00 by Wells Fargo
Dow Jones · 12/16/2025 15:12
Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8
Benzinga · 12/16/2025 15:02
MILESTONE PHARMACEUTICALS, INC. <MIST.O>: WELLS FARGO RAISES TARGET PRICE TO $8 FROM $4
Reuters · 12/16/2025 11:54
Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo
TipRanks · 12/16/2025 11:51
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher
Seeking Alpha · 12/15/2025 22:44
BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia
Reuters · 12/15/2025 18:44
Milestone Pharmaceuticals Raised to Buy From Hold by TD Cowen
Dow Jones · 12/15/2025 16:44
Milestone Pharmaceuticals Price Target Announced at $8.00/Share by TD Cowen
Dow Jones · 12/15/2025 16:44
TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target
Benzinga · 12/15/2025 16:34
Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/15/2025 16:06
Milestone Pharmaceuticals Price Target Raised to $8.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 12/15/2025 16:06
HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Raises Price Target to $8
Benzinga · 12/15/2025 15:56
BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, Zillow
Reuters · 12/15/2025 15:53
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval
TipRanks · 12/15/2025 15:10
More
Webull provides a variety of real-time MIST stock news. You can receive the latest news about Milestone Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.